NEX-I
NEX-I is a biotech company, founded in 2021. It has raised $63.7M across 3 rounds, most recently a $44.2M Series B in August 2025.
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Total Funding
- $63.7M
- Last Round
- $44.2M Series BAug 2025
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 15 investors for this company. The full record is or through the API.
About
NEX-I is a biotech firm pioneering a transformative shift in cancer immunotherapy, with ONCOKINE® as its first episode.
Summary
It lists 11–50 employees. It has raised $63.7M in total across 3 rounds, most recently a $44.2M Series B round in Aug 2025. Investors include DSC Investment, Atinum Investment and Hana Ventures.
Funding History
Aug 2025
Sign up to see all 3 events
Funding: Series B. Amounts, valuations, and investors where available.
Investors
DSC Investment
3 rounds
Atinum Investment
2 rounds
Hana Ventures
2 rounds
KB Investment
1 round
AJU IB Investment
1 round
Quad Partners
1 round
Horizon Partners
1 round
Company K Partners
1 round
Korea Investment & Securities
1 round
Industrial Bank of Korea
1 round
Yuanta Investment
1 round
Stonebridge Capital
1 round
TS Investment
1 round
CJ Investment
1 round
WONIK Investment Partners
1 round
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nex-i"><img src="https://indexed.vc/api/badge/company/nex-i" alt="NEX-I on Indexed.vc" width="260" height="76" /></a>